Fertilis is on a mission to eliminate infertility
IVF clinics cannot keep up with the demand for treatment. After 40 years of clinical practice, an IVF cycle is still more likely to fail than succeed. The science is brilliant, but the technology is elementary.
Fertilis’s team of scientists and globally recognized IVF experts is focused on eliminating infertility by transforming IVF.
We are building ground-breaking medical technology that removes the risk and variability from IVF treatment. Our micro-fertility devices reduce the stress on both embryos and embryologists, improving outcomes for both practitioners and patients. By providing innovation, precision, and control that enables standardization, our devices remove variability, decrease human error, improve consistency, and increase pregnancy rates
Fertilis’s microIVF device triples success rates per cycle. The typical IVF patient needs three cycles of IVF to become pregnant. A patient treated with a Fertilis device only needs two. When used to treat male infertility, our microICSI device doubles lab capacity, reduces cost, and improves results, reducing the time it takes to perform ICSI by 50%.
Fertilis is modernizing IVF with cutting edge micro-fertility devices that improve outcomes for patients and practitioners.
Other companies have focused on building technology that selects the best embryo for implantation. Fertilis’s devices are unique in that they improve embryo quality and quantity.
Fertilis’s pioneering 3D printed medical devices is a technology more than 20 years in the making. Fertilis Co-Founder and Chief Scientific Officer Professor Jeremy Thompson developed the idea in the late 1990s.
In 2017, he collaborated with co-members of the Centre for Nanoscale Biophotonics to develop his micro-device design, which was created using a micron-3D printer and revised and tested in collaboration with Professor David Gardner’s team at the University of Melbourne.
Meet the team of scientists and globally recognized IVF experts transforming IVF and eliminating infertility.
Jeremy is an internationally recognised professor who has authored more than 200 journal articles. He has held leadership positions at the University’s Robinson Research Institute and the Australian Research Council’s Centre of Excellence for Nanoscale Biophotonics. From 1999 to 2004, he gained clinical experience serving as the director of IVF clinic Repromed.
He developed his commercialization experience through a ten-year partnership between The University of Adelaide, Cook Medical LLC, and Vrije Universiteit Brussel, Belgium. He has initiated a previous start-up, ART Lab Solutions Pty Ltd., and he was the commercialisation champion within the Robinson Research Institute.
Jeremy is a Fellow of the Society for Reproductive Biology, and in 2016, he was awarded its highest honor, The Founders Lecture. He holds a PhD in Veterinary Anatomy (Reproduction) from the University of Queensland.
He is a Redmond Barry Distinguished Professor at the School of BioSciences, University of Melbourne, and has served as the Scientific Director of Melbourne IVF since 2017. David has made vast contributions to the field of reproductive biology, which were recognized in both his 2017 election into the Australian Academy of Science and his winning of the American Society of Reproductive Medicine’s highest honor, the Distinguished Researcher Award. In June 2022 he was awarded the “Order of Australia, AM” for “Service to Reproductive Medicine and Education.”
He has authored more than 300 publications, and he continues to lead innovation in human IVF. As the Scientific Director of Melbourne, he has run successful clinical trials in both embryo culture and the use of artificial intelligence in IVF.
David holds a PhD in Biological Sciences from the University of York, UK.
A serial entrepreneur, Marty has previously founded eight start-ups– including medical assistance technology firm GCL Systems– which have collectively raised over $20M in private capital.
Since 2001, Marty has sat on the board of various government and private investment committees focused on increasing investment into the commercialization of Australian research, including the Investment Committee of Innovation and Science Australia which governs the venture capital sector in Australia and Young and Well CRC, Australia’s first Collaborative Research Centre exploring the role of technology in improving the mental health of young people.
Prior to joining Fertilis, Allison successfully developed and managed award-winning products throughout their lifecycle, from concept prototyping to market launch and manufacturing sustainment. As the director of product development at Genea Biomedx, she led the IVF portfolio’s product development and engineering functions. At Leica Biosystems, a global leader in cancer diagnostics, Allison was program manager for their premium tissue processing platform, leading new product development and manufacturing sustainment. Previously, she was project leader and senior mechanical engineer at the consulting group Invetech, where she worked with health and life science leaders to develop breakthrough solutions, from life-saving point of care devices to diagnostics automation.
Allison holds a Bachelor of Engineering (Mech), Hons 1 from Monash University, Melbourne.
Roger has been working with Fertilis since 2019 when he began assessing and validating commercial opportunities, creating financial models, and proposing incremental prototype delivery to de-risk the business. He is a critical and creative thinker who solves business challenges by looking at them from multiple angles while staying close to the needs of the end user.
Hanna completed a transdisciplinary project bridging across Reproductive Biology, Chemistry, and Physics as a PhD student of the Australian Research Council’s Centre of Excellence for Nanoscale BioPhotonics.
With nine publications to her name, she is continuing her career with collaborations across disciplines within Fertilis to transition new discoveries to exciting applications within the IVF clinic.She holds a PhD in Medicine (Reproductive Biology) from the University of Adelaide.
At Fertilis, her skills and knowledge as a clinical research scientist are focused towards helping automate/simplify ICSI, IVF insemination techniques, and embryo culture.